2 terminated, 1 active not recruiting, 1 no longer available, 1 withdrawn. 2 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow omburtamab I-131: new trials by email Literature Review of omburtamab I-131 trials Research Report on omburtamab I-131
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma Irinotecan, Temozolomide, Bevacizumab - Recurrent Medulloblastoma, Recurrent Ependymoma | Phase 2 | Active not recruiting | Pediatric Brain Tumor Consortium | 62 | 2022-04-04 | 2026-07-28 |
| 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma 131I-Omburtamab, Convention Enhanced Delivery - DIPG | Phase 1 | Withdrawn | Y-mAbs Therapeutics | 2022-03-01 | 2023-06-26 | |
| 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases 131I-omburtamab - Neuroblastoma, CNS Metastases | Phase 2 / Phase 3 | Terminated | Y-mAbs Therapeutics | 52 | 2018-12-11 | 2024-02-13 |
| Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer Iodine I 131 MOAB 8H9 - Brain and Central Nervous System Tumors, Neuroblastoma | Phase 1 | Terminated | Y-mAbs Therapeutics | 177 | 2004-02-05 | 2023-12-26 |
| 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults 131I-omburtamab - Central Nervous System/Leptomeningeal Neoplasms | No longer available | Memorial Sloan Kettering Cancer Center | 2025-08-01 |
Medulloblastoma (3) · Neuroblastoma (3) · Meningeal Carcinomatosis (2) · Rhabdoid Tumor (2) · Rhabdomyosarcoma (2) · Brain Neoplasms (1) · Central Nervous System Neoplasms (1) · Desmoplastic Small Round Cell Tumor (1) · Ependymoma (1) · Hepatoblastoma (1) · Meningeal Neoplasms (1) · Neuroectodermal Tumors, Primitive (1) · Neuroectodermal Tumors, Primitive, Peripheral (1) · Osteosarcoma (1) · Pinealoma (1)
Y-mAbs Therapeutics (3) · Memorial Sloan Kettering Cancer Center (1) · Pediatric Brain Tumor Consortium (1)
United States (4) · Denmark (1) · Japan (1) · Spain (1)
John Roemer, MD (1) · Kim Kramer, MD (1) · Matthias Karajannis, MD, MS (1) · Sameer Farouk Sait, MD (1)
PMID 33047248, PMID 36371226, PMID 38464207, PMID 39083105
UM1CA081457 (1)